Completed Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors NCT03037385 Conditions Adenocarcinoma, Adenocarcinoma, Papillary, Bronchial Diseases, +55 more Locations Mayo Clinic Hospital — Phoenix, Arizona, United States UC Irvine Medical Center — Orange, California, United States University of Colorado Anschutz Medical Campus — Aurora, Colorado, United States Georgetown University Medical Center — Washington D.C., District of Columbia, United States View all 71 locations View more locations Show fewer locations Loading locations... View Trial Details
